PATENT CLAIM ANALYSIS

Application Number: 15952017
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["548", "112000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Claim (Index 1):
A method of treating arthritis pain comprising orally administering zoledronic acid to a human being in need thereof, wherein the amount of the zoledronic acid orally administered to the human being within a period of about one month is about 150 mg to about 250 mg, wherein each time the zoledronic acid is orally administered, the human being fasts for at least one hour prior to oral administration of the zoledronic acid and the human being fasts for at least one hour after oral administration of the zoledronic acid.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.25
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15385415', '15348842', '15439774', '15354908', '15623274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8025841545749746
- 35 USC 102 Novelty (BERT): 0.6260032952626748
- Combined Prediction Score: 0.7849260686437446
- Mean Citation Score: 673.67468
- Max Citation Score: 681.28015
- Similarity Product: 507.7193528333754

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test